ReviewCurrent hematologic malignancy reports2019
Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors.
Review in Current hematologic malignancy reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.Blood advances · 2021Trial
- NK Cells in Myeloproliferative Neoplasms (MPN).Cancers · 2021Review
- The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms.Blood research · 2021Review
- Exosomes and Extracellular Vesicles in Myeloid Neoplasia: The Multiple and Complex Roles Played by These "Biology · 2021Review
- Article
- The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms.Cancer medicine · 2020Article
- Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.Hematological oncology · 2020Review
- Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms.Expert review of hematology · 2020Article
- Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms.Cancers · 2020Review
- Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to.Annals of hematology · 2020Review
- Molecular screening for an underlying myeloproliferative neoplasm in patients with stroke: who and how?Blood research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewWith increased understanding of the pathobiology of myeloproliferative neoplasms (MPNs), multiple new agents are now being investigated. We aim to cover some of the current treatment options for MPNs and discuss new agents in development. RECENT
findingsThe introduction of ruxolitinib improved the treatment of many patients with intermediate and higher risk myelofibrosis. However, ruxolitinib monotherapy does not benefit all patients, and not all patients can receive this therapy due to limiting cytopenias. The unraveling of new molecular abnormalities and cellular pathways led to the development of several novel targeted agents that are currently under investigation in clinical trials. These agents have different mechanisms of action and are being used either alone or in combination with ruxolitinib. Novel targets include inhibition of apoptosis, the tumor microenvironment, telomerase enzyme action, immunotherapy, and fibrosis with associated cytokines. We comprehensively review and summarize the available preclinical and clinical trials with novel agents for MPNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.